BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile

BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile

The objective of the present study was to elucidate the effect of BMN 673 (talozoparib) on BRCA1 mutant (HCC1937) and wild‐type (MDA‐MB‐231) triple negative breast cancer (TNBC). The in vitro cytotoxicity results indicated that BMN 673 had considerable inhibitory effects on HCC1937 and MDA‐MB‐231 ce...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of biochemical and molecular toxicology 2019-05, Vol.33 (5), p.e22286-n/a
Hauptverfasser: Guney Eskiler, Gamze, Cecener, Gulsah, Egeli, Unal, Tunca, Berrin
Format: Artikel
Sprache:eng
Schlagworte:
Adenosine diphosphate
Apoptosis
apoptotic death
BMN 673 (talozoparib)
BRCA
BRCA1 protein
Breast cancer
Cancer
Cell death
Cytotoxicity
Gene expression
Inhibitors
Molecular modelling
Poly(ADP-ribose) polymerase
Ribose
Targeted cancer therapy
Toxicity
triple negative breast cancer
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The objective of the present study was to elucidate the effect of BMN 673 (talozoparib) on BRCA1 mutant (HCC1937) and wild‐type (MDA‐MB‐231) triple negative breast cancer (TNBC). The in vitro cytotoxicity results indicated that BMN 673 had considerable inhibitory effects on HCC1937 and MDA‐MB‐231 cell lines by inducing apoptosis, multicaspase activity, G2/M arrest, and altering the expression levels of apoptosis‐related genes (P 
ISSN:1095-6670
1099-0461
DOI:10.1002/jbt.22286